Over the past decade, many pharmaceutical companies have developed and implemented continuous manufacturing technologies. However, these efforts are very different in nature and scope (see figure below), with varying degrees of risks and benefits.
Risk vs. Reward for Different Continuous Manufacturing Efforts
Whereas many companies are using single continuous unit operations in otherwise batch processes (A) or integrated solutions for part of the manufacturing process (B), CONTINUUS is leveraging end-to-end ICM, which integrates both the upstream production of API and the downstream formulation steps into a single seamless continuous process (C). Critical enabling components include:
By leveraging different aspects of ICM, CONTINUUS Pharmaceuticals is able to offer clients a range of solutions, based on the specific requirements.